[Not Available].
| Autor: | Muret P; UMR 645 - IFR 133, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, France. Electronic address: patrice.muret@univ-fcomte.fr., Piedoux S; UMR 645 - IFR 133, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, France., Solas C; Laboratoire de Pharmacocinétique et Toxicologie, Hôpital de La Timone, Marseille, France., Quaranta S; Laboratoire de Pharmacocinétique et Toxicologie, Hôpital de La Timone, Marseille, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Therapie [Therapie] 2011 May-Jun; Vol. 66 (3), pp. 187-95. |
| DOI: | 10.2515/therapie/2011030 |
| Abstrakt: | Nevirapine, a HIV non nucleosidic reverse transcriptase inhibitor, displays an inter-individual variability in its pharmacokinetics parameters, related to its hepatic metabolism. Based on literature, is the nevirapine therapeutic drug monitoring relevant? In naïve and pre-treated HIV infected patients, the probability of achieving and maintaining an undetectable HIV viral load was significantly associated with a nevirapine plasma trough concentration (Ctrough) >4000 ng/mL. The probability of virologic failure was significantly associated with a Ctrough <3000 ng/mL. Concerning the exposure-toxicity relationship, the emergence of hepatotoxicity was more frequently associated with high Ctrough, especially in case of HCV coinfection. Non-randomized studies have reported the interest of nevirapine therapeutic drug monitoring to optimize the virologic response and, to a lesser extent, to prevent hepatotoxicity. Therefore, the level of evidence of the interest of nevirapine therapeutic drug monitoring is "recommended". (Copyright © 2011 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|